Table 3. Orphan drug programs run by Chinese drug companies.

Company	Drug name	Indication	Stage of development
Chipscreen	Chidamide	PTCL	launched in China
Shanghai Genomics	Aisi Rui, Etuary	IPF	launched in China
Hua Medicine	HME01	PD-LID, FXS	preclinical
Prosit Sole Biotechnology	multiple products	chronic norovirus infection, articular cartilage injury, refractory gout, lupus renal failure & uremia	preclinical

FXS, fragile X syndrome; IPF, idiopathic pulmonary fibrosis; PD-LID, Parkinson's disease — L-dopa-induced dyskinesia; PTCL, peripheral T-cell lymphoma.